Zura Bio Ltd. Files 8-K on Warrants

TL;DR

Zura Bio Ltd. filed an 8-K on warrants. Standard disclosure.

AI Summary

Zura Bio Ltd. filed an 8-K on August 20, 2025, reporting on warrants. The filing details information related to the company's warrants, which are financial instruments that give the holder the right, but not the obligation, to buy or sell an underlying security at a specified price and time. This filing is a standard disclosure for companies with outstanding warrants.

Why It Matters

This filing provides transparency to investors regarding the terms and status of Zura Bio Ltd.'s outstanding warrants, which can impact the company's capital structure and potential dilution.

Risk Assessment

Risk Level: low — This is a routine regulatory filing concerning warrants and does not indicate any immediate financial distress or significant operational changes.

Key Players & Entities

• Zura Bio Ltd (company) — Registrant
• August 20, 2025 (date) — Date of Report
• Warrants (financial_instrument) — Subject of the filing
• Cayman Islands (jurisdiction) — State or other jurisdiction of incorporation
• 001-40598 (commission_file_number) — SEC File Number

FAQ

Key Financial Figures

• $0.0001 — ed Class A Ordinary Shares, par value $0.0001 per share ZURA The Nasdaq Stock Mar

Filing Documents

• tm2523875d1_8k.htm (8-K) — 29KB
• tm2523875d1_ex99-1.htm (EX-99.1) — 6KB
• tm2523875d1_ex99-1img001.jpg (GRAPHIC) — 3KB
• 0001104659-25-080521.txt ( ) — 204KB
• zura-20250820.xsd (EX-101.SCH) — 3KB
• zura-20250820_lab.xml (EX-101.LAB) — 33KB
• zura-20250820_pre.xml (EX-101.PRE) — 22KB
• tm2523875d1_8k_htm.xml (XML) — 4KB

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On August 20, 2025, Zura Bio Limited (" ZURA ", the " Company ") issued the press release attached hereto as Exhibit 99.1 to this Current Report on Form 8-K. By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated August 20, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZURA BIO LIMITED Date: August 20, 2025 By: /s/ Kim Davis Kim Davis Chief Operating Officer, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR